Elite Pharmaceuticals (OTCMKTS:ELTP) Issues Quarterly Earnings Results

Elite Pharmaceuticals (OTCMKTS:ELTP) announced its earnings results on Thursday. The specialty pharmaceutical company reported $0.01 EPS for the quarter, Zacks reports. Elite Pharmaceuticals had a net margin of 40.19% and a return on equity of 44.58%.

Elite Pharmaceuticals Stock Up 2.1%

ELTP stock traded up $0.01 during midday trading on Thursday, hitting $0.24. The company’s stock had a trading volume of 225,848 shares, compared to its average volume of 678,204. The company’s fifty day moving average price is $0.25 and its 200 day moving average price is $0.34. The company has a debt-to-equity ratio of 0.03, a current ratio of 3.76 and a quick ratio of 2.97. Elite Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $0.69. The stock has a market capitalization of $263.98 million, a P/E ratio of 6.13 and a beta of 0.44.

Elite Pharmaceuticals Company Profile

Elite Pharmaceuticals is a specialty pharmaceutical company focused on developing, manufacturing, and marketing generic and branded drug products. Its work includes oral dosage medicines, with an emphasis on controlled-release formulations and products designed to address medication misuse. The company has developed and commercialized prescription products in several therapeutic categories, including treatments for attention-deficit/hyperactivity disorder and pain. Its business also includes advancing additional products through development and regulatory review.